睿知中国疾病研究地图
候选清单0

正在招募食管鳞状细胞癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study

ClinicalTrials.gov 上登记的一项食管鳞状细胞癌开放试验,由空军军医大学唐都医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方空军军医大学唐都医院Tangdu Hospital西安医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06663059,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 9

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(9 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Histologically or cytologically confirmed esophageal squamous cell carcinoma.

    入选标准第 2 条

  3. Locally advanced thoracic esophageal cancer assessed by CT/MRI/EUS, with clinical staging T1b-4aN+M0 or T2-4N0M0 (T2N0 patients must have high-risk factors such as lymphovascular invasion [LVI], tumor size ≥3 cm, or poor differentiation) (according to AJCC 8th edition).

    入选标准第 3 条

  4. Female participants of childbearing potential must have a negative serum pregnancy test within 72 hours before starting the study drug and must use effective contraception (e.g., intrauterine device, contraceptive pills, or condoms) during the study and for at least 3 months after the last dose. Male participants with a fertile partner must be surgically sterilized or agree to use effective contraception during the study and for 3 months after the last dose.

    入选标准第 22 条

    Immunosuppressive drugs or systemic steroids (doses > 10 mg/day of prednisone or equivalent) within 2 weeks prior to the first use of the study drug; inhaled or topical steroids and adrenal corticosteroids for non-active autoimmune diseases are allowed.

    排除标准第 8 条

    Diagnosis of other malignant tumors within 5 years prior to the first use of the study drug, unless it is a low-risk malignancy (5-year survival rate > 90%), such as fully treated basal cell carcinoma, squamous cell skin cancer, or cervical carcinoma in situ.

    排除标准第 17 条

  5. ECOG Performance Status 0-1.

    入选标准第 6 条

  6. **Hematology** (no use of blood components, growth factors, white blood cell stimulants, platelet stimulants, or anemia-correcting drugs within 14 days before the first use of the study drug):

    入选标准第 11 条

    Neutrophil count ≥1.5 × 10\^9/L

    入选标准第 12 条

    Platelet count ≥100 × 10\^9/L

    入选标准第 13 条

    Hemoglobin ≥90 g/L

    入选标准第 14 条

    Total bilirubin ≤1.5 × ULN

    入选标准第 16 条

    ALT ≤2.5 × ULN, AST ≤2.5 × ULN

    入选标准第 17 条

    Serum creatinine ≤1.5 × ULN, or creatinine clearance ≥50 mL/min

    入选标准第 18 条

    International Normalized Ratio (INR) ≤1.5 × ULN

    入选标准第 20 条

    Activated Partial Thromboplastin Time (APTT) ≤1.5 × ULN

    入选标准第 21 条

  7. Active pulmonary tuberculosis infection discovered by medical history or CT, or history of active pulmonary tuberculosis within the past year, or history of active pulmonary tuberculosis more than 1 year ago without formal treatment.

    排除标准第 15 条

  8. History of immunodeficiency, including positive HIV test, or other acquired or congenital immunodeficiencies, or history of organ transplantation or allogeneic bone marrow transplantation.

    排除标准第 12 条

    Active hepatitis B (HBV DNA ≥ 2000 IU/mL or 10\^4 copies/mL) or hepatitis C (positive HCV antibody, and HCV RNA above the lower limit of detection).

    排除标准第 16 条

  9. Pregnant or breastfeeding women.

    排除标准第 18 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06663059,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Written informed consent must be signed, and the participant must voluntarily join the study.
  2. Histologically or cytologically confirmed esophageal squamous cell carcinoma.
  3. Locally advanced thoracic esophageal cancer assessed by CT/MRI/EUS, with clinical staging T1b-4aN+M0 or T2-4N0M0 (T2N0 patients must have high-risk factors such as lymphovascular invasion [LVI], tumor size ≥3 cm, or poor differentiation) (according to AJCC 8th edition).
  4. Expected to achieve R0 resection.
  5. Age between 18 and 75 years, regardless of gender.
  6. ECOG Performance Status 0-1.
  7. No prior treatment for esophageal cancer, including radiotherapy, chemotherapy, or surgery.
  8. Planning to undergo surgery after completing neoadjuvant therapy.
  9. No contraindications for surgery.
  10. Normal major organ functions, including:
  11. **Hematology** (no use of blood components, growth factors, white blood cell stimulants, platelet stimulants, or anemia-correcting drugs within 14 days before the first use of the study drug):
  12. Neutrophil count ≥1.5 × 10\^9/L
  13. Platelet count ≥100 × 10\^9/L
  14. Hemoglobin ≥90 g/L
  15. **Biochemistry**:
  16. Total bilirubin ≤1.5 × ULN
  17. ALT ≤2.5 × ULN, AST ≤2.5 × ULN
  18. Serum creatinine ≤1.5 × ULN, or creatinine clearance ≥50 mL/min
  19. **Coagulation**:
  20. International Normalized Ratio (INR) ≤1.5 × ULN
  21. Activated Partial Thromboplastin Time (APTT) ≤1.5 × ULN
  22. Female participants of childbearing potential must have a negative serum pregnancy test within 72 hours before starting the study drug and must use effective contraception (e.g., intrauterine device, contraceptive pills, or condoms) during the study and for at least 3 months after the last dose. Male participants with a fertile partner must be surgically sterilized or agree to use effective contraception during the study and for 3 months after the last dose.
  23. Good compliance with the study and cooperation with follow-up.

排除标准:Exclusion Criteria:

  1. Tumor clearly invading adjacent organs (e.g., major arteries or trachea).
  2. Supraclavicular lymph node metastasis.
  3. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
  4. Poor nutritional status, BMI < 18.5 kg/m²; if corrected with symptomatic nutritional support before randomization, may be considered for inclusion after assessment by the principal investigator.
  5. History of allergy to monoclonal antibodies, Adebrelimab or its components, paclitaxel, cisplatin, or other platinum-based drugs.
  6. Previous or current treatment with:
  7. Any tumor-directed radiotherapy, chemotherapy, or other anti-tumor drugs.
  8. Immunosuppressive drugs or systemic steroids (doses > 10 mg/day of prednisone or equivalent) within 2 weeks prior to the first use of the study drug; inhaled or topical steroids and adrenal corticosteroids for non-active autoimmune diseases are allowed.
  9. Live attenuated vaccines within 4 weeks prior to the first use of the study drug.
  10. Major surgery or severe trauma within 4 weeks prior to the first use of the study drug.
  11. Active autoimmune diseases or a history of autoimmune diseases, including but not limited to: interstitial pneumonia, colitis, hepatitis, pituitaryitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism (considered if on hormone replacement therapy); psoriasis or childhood asthma/allergy in complete remission without intervention can be considered, but those requiring bronchodilators for medical intervention cannot be included.
  12. History of immunodeficiency, including positive HIV test, or other acquired or congenital immunodeficiencies, or history of organ transplantation or allogeneic bone marrow transplantation.
  13. Poorly controlled cardiac symptoms or diseases, including but not limited to: (1) NYHA Class II or higher heart failure, (2) unstable angina, (3) myocardial infarction within 1 year, (4) clinically significant supraventricular or ventricular arrhythmias not controlled or poorly controlled after clinical intervention.
  14. Severe infection (CTCAE > 2) within 4 weeks prior to the first use of the study drug, such as severe pneumonia, bacteremia, or infection complications requiring hospitalization; active pulmonary inflammation on baseline chest imaging, symptoms and signs of infection within 14 days prior to the first use of the study drug, or need for antibiotic treatment, except for prophylactic use.
  15. Active pulmonary tuberculosis infection discovered by medical history or CT, or history of active pulmonary tuberculosis within the past year, or history of active pulmonary tuberculosis more than 1 year ago without formal treatment.
  16. Active hepatitis B (HBV DNA ≥ 2000 IU/mL or 10\^4 copies/mL) or hepatitis C (positive HCV antibody, and HCV RNA above the lower limit of detection).
  17. Diagnosis of other malignant tumors within 5 years prior to the first use of the study drug, unless it is a low-risk malignancy (5-year survival rate > 90%), such as fully treated basal cell carcinoma, squamous cell skin cancer, or cervical carcinoma in situ.
  18. Pregnant or breastfeeding women.
  19. Any condition that, in the investigator's judgment, may lead to withdrawal from the study, such as other serious illnesses (including mental illnesses) requiring concurrent treatment, alcohol or drug abuse, family or social factors that may affect the participant's safety or compliance.

引自 ClinicalTrials.gov, NCT06663059, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06663059,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06663059